ClinicalTrials.gg
CompletedNCT04902807ATRACTionUpdated Sep 18, 2026

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

An observational study in Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia and Autoimmune Diseases, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 1 site in France. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
325
Ages
1 Year to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 96 studies in Autoimmune Diseases with a site in France — 32 open to participants now, 37 under way, 8 of them phase 3. Autoimmune Diseases · France.

Enrollment
19th of 40
325 · median 304
Started
2021
with 12 others
Observational
40 of 96
17 open now
Registered
55th of 96
by date
Lead sponsor
3 of 96
Institut National de la Santé Et de la Recherche Médicale, France

Among the 96 studies in Autoimmune Diseases with a site in France, this one is the 19th largest by enrollment of the 40 observational ones that give a count, is one of 13 that started in 2021, is one of 40 observational ones, and was the 55th registered.

Autoimmune Diseases

804 studies on the registry are indexed under Autoimmune Diseases; 273 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

32 of the 96 studies in Autoimmune Diseases with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 1 Year to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 96 studies in Autoimmune Diseases with a site in France, or all of them as a file.
02

Study summary

The main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

Read the detailed description

Primary Immune deficiencies (PIDs) are a group of monogenic diseases related to developmental or functional dysfunction of one or several immune cell types. Individually there are rare entities, but collectively they group several thousands of patients.

Approximately 500 000 patients suffer from PIDs worldwide, making their management a true health-care concern. According to European Society for Immunodeficiencies (ESID), the age group in which PIDs is most frequently diagnosed is under 19 years of age (62%)1. PIDs are causing susceptibility to severe and life-threatening infections by common pathogens, but they also predispose to cancer and can initially manifest as autoimmune and inflammatory diseases.

Multiple mechanisms underlie the development of autoimmunity/inflammation in PIDs. Moreover, their development can be influenced by the composition of the microbiota, which shapes host metabolic and immune functions and can be modified by many environmental factors. In the last two decades a particular emphasis was given to the elucidation of the genomic mutations causing PIDs. This led to a burst of genetic diagnosis as the numbers of known monogenic causes of PIDs rose from around 200 in 2010 to more than 310 in 2017. These genomic approaches revealed that: 1) a given monogenic defect can lead to very dissimilar clinical presentations, disproving the initial concept that a monogenic defect is associated with specific clinical manifestations ; and 2) the number of cases of autosomal dominant genetic deficiencies has increased, with sometimes a partial clinical penetrance so that some relatives carrying the causal genetic variant remain asymptomatic. Hence, onset and presentation of autoimmune and inflammatory diseases in PIDs is highly unpredictable.

PIDs with autoimmunity/inflammation usually require life-long symptomatic treatments including broad immunosuppression or immunotherapies. On the long term, such treatments can have important side effects or poor efficacy and they result in high burden cost. It is therefore crucial to diagnose PIDs as early as possible in order to select the most efficient therapy based not only on clinical features as it is nowadays, but to include the underlying molecular cause of immune dysregulation.

The central goal of this project is to explain the very variable outcome of monogenic autoimmune and inflammatory diseases and to define predictive biomarkers in order to stratify patients and to optimize therapeutic choices.

03

Conditions studied

  • Autoimmune Lymphoproliferative Syndrome
  • Autoimmune Cytopenia
  • Autoimmune Diseases
  • Autoimmune Anemia
  • Autoimmune Thrombocytopenia
  • Autoimmune Hepatitis
  • Autoimmune Diabetes
  • Autoimmune Rheumatologic Disease
  • Systemic Lupus Erythematosus
  • Juvenile Idiopathic Arthritis
  • Hemophagocytic Lymphohistiocytoses
  • EBV Lymphoproliferation
  • RAS-Associated Autoimmune Leucoproliferative Disease
  • Primary Immunodeficiency
  • APECED
  • IPEX
  • BENTA
  • Enteropathy, Autoimmune
  • Combined Immunodeficiency
  • IBD
04

Who can participate

Ages eligible
1 Year to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with PIDs and autoimmunity/inflammation related to known and unknown genetic defects (ALPS, Cytopenia, Enteropathy-IBD, pSLE, JIA, FHL, CA-EBV, CID) and their healthy relatives (controls) will be recruited in 2 clinical services of Necker hospital: Paediatric Rhumatology Immuno Hematology department Department, and paediatric Paediatric Gastroenterology department Department.

Unrelated controls will be recruited in the Paediatric Rhumatology Immuno Hematology Department, the Paediatric Gastroenterology Department,also be recruited in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery within patients hospitalised for a surgery and not affected by an immune-related disease or a cancer.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion Criteria for controls (patients relatives and unrelated subjects):

  • Individuals aged\<18 y/o.
  • Individuals > 6 kg
  • Individuals not affected by an immune-related disease or not affected by cancer
  • Individuals whose parents have signed an enlightened consent.

Inclusion criteria

Inclusion criteria for patients

  • Individuals with health insurance.
  • Patients treated at Necker hospital with PIDs and autoimmunity/inflammation related to known genetic defects (cytopenia, Enteropathy Inflammatory bowel disease (IBD), Systemic Lupus Erythematosus (SLE), Juvenile Idiopathic Arthritis (JIA), Familial Hemophagocytic Lymphohistiocytosis (FHL), chronic EBV infection associated (Ca-EBV) with EBV-infected T and/or Natural Killer (NK) cells and with a high risk to develop macrophage activation syndrome similar to FHL. See table below for diagnosis inclusion criteria.
  • Individuals aged\<18 y/o.
  • Individuals > 9 kg
  • Patients whose parents have signed an enlightened consent.

Exclusion criteria

Exclusion Criteria:

  • Intake of antibiotics within 2 weeks prior inclusion
  • Absence of parent's or child consent form
  • Cytotoxic cancer treatments
  • antiviral treatments (, hepatitis …)
  • Short term life-threatening conditions
  • Individuals placed under judicial protection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
325 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients

    based on the potential for inclusion of patient's cohort followed in Necker hospital with PIDs and poly-autoimmunity related to known genetic defects. Recruitments will be made at Pediatric Rheumatology Immuno Hematology department, and paediatric Gastroenterology department (n=250). Collection of blood, urine and stools at inclusion and blood at 12 months consultation/ follow-up.

    Biological: Collection of samples

  • Patients' relatives (control)

    Brothers or sisters of the patients (n=125). Collection of blood, urine and stools at inclusion.

    Biological: Collection of samples

  • Patients with unrelated diseases (control)

    Recruitments will be made at the Paediatric Gastroenterology Department, in the Department of Paediatric Visceral and Urologic Surgery and the Department of Maxillofacial Surgery and Paediatric Plastic Surgery at Necker's Hospital. Participants will be included if not diagnosed PIDs and poly-autoimmunity (n=125). Collection of blood, urine and stools.

    Biological: Collection of samples

Interventions

  • BiologicalCollection of samples

    Blood, Urine and Stool samples will be collected from the participants.

06

What researchers measure

Primary outcomes

  1. Generate a diagnosis and therapeutic-decision tools

    Identification of molecular causes of PIDs with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomic, epigenomics, proteomic, metagenomic, metabolomics and lipidomics).

    Time frame: 5 years

Secondary outcomes

  1. 1- Development of an atlas of molecular interactions leading to autoimmunity and inflammation

    Research tool integrating transcriptomic, proteomic, epigenetic, metabolomic and lipidomics data of pediatric affected patients as well as healthy pediatric individuals This atlas will be available widely to the public and private research community.

    Time frame: 5 years

  2. 2 - To develop an artificial intelligent online application

    The decision support tool will be interoperable with any clinical information system and will be clinically validated.

    Time frame: 5 years

  3. 3- Ancillary study (pilot study)

    i. Validation of candidate biomarkers associated to diagnosis and prognosis of Juvenile Idiopathic Arthritis patients ; ii. Definition of a specific clinical outcome and early quantification of the performance of a diagnostic decision tool based on omics signatures (proof of concept)

    Time frame: 5 years

07

Study locations

1 site
  • hôpital Necker Enfants Malades
    Paris, France
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in May 2025, 44 months.

Of 77 non-industry observational studies under Autoimmune Diseases, half reached primary completion within 121 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 309. This study's 44 months is below that.

Counting every sponsor, half of 92 studies reached it within 121 months; a quarter within 41 and three quarters within 309.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2021
First posted
May 26, 2021
StartActual
Sep 7, 2021
Primary completionActual
May 14, 2025
CompletionActual
Oct 21, 2025
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04902807
Responsible party
Sponsor
First posted
May 26, 2021
Start date
Sep 7, 2021
Primary completion
May 14, 2025
Completion
Oct 21, 2025
Last update
Sep 18, 2026

Study contacts

Frédéric Rieux-Laucat
principal investigator · Institut Imagine

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion